Logotype for Tenet Healthcare Corporation

Tenet Healthcare (THC) Q3 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Tenet Healthcare Corporation

Q3 2024 earnings summary

8 Jul, 2026

Executive summary

  • Q3 2024 net operating revenues reached $5.12 billion, with consolidated adjusted EBITDA of $978 million, up 14.5–15% year-over-year, and net income available to shareholders of $472 million, reflecting gains from major hospital divestitures.

  • Ambulatory segment delivered 18.6–19% adjusted EBITDA growth to $439 million, with robust volume and revenue per case increases; hospital segment adjusted EBITDA grew 11% (24% ex-divestitures).

  • Major divestitures in Alabama, South Carolina, and California generated $2.9 billion in pre-tax gains and improved the hospital portfolio's return profile.

  • Free cash flow for Q3 was $829 million, supporting investments and share repurchases; cash on hand at quarter-end was $4.09 billion.

  • Share repurchases totaled 5.6 million shares for $672 million year-to-date, with a new $1.5 billion program authorized.

Financial highlights

  • Q3 2024 net operating revenues were $5.12 billion (up 1.1% year-over-year); adjusted EBITDA margin was 19.1%, up from 16.9% in Q3 2023.

  • Q3 2024 net income was $472 million (9.2% margin); diluted EPS was $4.89, adjusted diluted EPS $2.93.

  • Free cash flow for Q3 2024 was $829 million, up from $327 million in Q3 2023.

  • Cash and cash equivalents at September 30, 2024, were $4.09 billion.

  • Net debt to adjusted EBITDA ratio improved to 2.22x at September 30, 2024.

Outlook and guidance

  • FY 2024 adjusted EBITDA guidance raised to $3.9–$4.0 billion, with net operating revenues expected at $20.6–$20.8 billion.

  • FY 2024 free cash flow projected at $975 million to $1.225 billion, with adjusted free cash flow at $1.15–$1.35 billion.

  • Ambulatory segment FY 2024 net revenue per surgical case expected to rise 6–7%; hospital admissions up 4–5%.

  • Capital expenditures for 2024 projected at $800–$900 million, focused on ambulatory expansion and hospital upgrades.

  • Management expects to offset divested facility EBITDA and Medicaid adjustments in 2025 through volume growth, pricing, and efficiencies.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more